[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"knee-replacement-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:knee-replacement-surgery":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100534115","phase-2-cannabidiol-for-postoperative-opioid-reduction-in-primary-total-knee-arthroplasty-100534115",false,"NCT06234631","Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty","Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty - a Randomized, Two by Two Factorial, Double-blind, Placebo-controlled Clinical Trial","CORK","Inclusion Criteria:\n\n* Willing and able to read, understand, and sign the informed consent (English)\n* Willingness to participate in all study measures and restrictions, including patient-reported outcomes and longitudinal follow-up\n* Scheduled for surgery: primary total knee arthroplasty\n* Primary diagnosis of osteoarthritis of the surgical knee\n* Individuals of reproductive potential must agree to use acceptable birth control (defined in manual of operating procedures). This includes currently practicing an effective form of two types of birth control for women of childbearing potential, which are defined as those, alone or in combination, that result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly from the screening visit until 28 days after the last study drug administration.\n* Participants must also agree not to donate sperm or eggs during study drug administration\n* Ability to take and to swallow the study medication and be willing to adhere to the treatment regimen\n* Agreement to adhere to Lifestyle Considerations (see protocol) throughout study duration\n\nExclusion Criteria:\n\n* Revision or bilateral total knee arthroplasty\n* Individuals receiving or actively applying for worker's compensation or disability and other aspects associated with potential secondary gain (postoperative disability for recovery is permitted)\n* Severe physical impairment or clinically significant illness (e.g., blindness, paraplegia)\n* Co-morbid medical conditions that may significantly impair physical functional status (e.g., current non-skin malignancies, solid organ transplant in the past year)\n* Illicit drug use (other than cannabis). Unreported opioid use would be exclusionary but reported prescribed opioid use is allowed (e.g. patient denies opioid use but is found to be positive on the urine drug screen)\n* Self-reported use of cannabis products within the 7 days prior to starting study drug\n* Self-reported use of cannabis products within the 8-30 days prior to starting study drug AND either a failed drug screen or inability to confirm successful washout (Note - may be rescreened with appropriate wash-out period)\n* High daily preoperative opioid dose\n* Individuals with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, history of traumatic brain injury\u002Fhead injury, and seizures\n* Individuals with significant illness (e.g., cancer) and\u002For clinically significant labs (e.g. labs measured by complete blood count (CBC) and basic chemistry with values meaningfully outside of the normal range \\[abnormal levels to be reviewed by the Principal Investigator or prescribing provider\\])\n* Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in this study (e.g., psychosis, suicidal ideation; note that stable anxiety and depression are not exclusions)\n* Pregnant or nursing women (total joint arthroplasty is typically not indicated in this group of patients)\n* Self-reported liver cirrhosis\n* Self-reported uncontrolled diabetes\n* Self-reported active hepatitis (any etiology, including infectious, autoimmune, or alcohol-related)\n* Blood pressure at screening above 180 millimeters of mercury (mmHg) systolic and\u002For 120 mmHg diastolic; if value exceeds the set point, potential participants will have repeat assessment within 5 minutes for up to two additional measurements.\n* Resting heart rate at screening less than 50 beats per minute (bpm) or greater than 100 bpm; if value exceeds the set point, potential participants will have repeat assessment within 5 minutes for up to two additional measurements.\n* Elevated liver enzymes and bilirubin (measured by blood test at screening)\n* Serum total bilirubin ≥ 2.5 milligrams (mg) per deciliter (dL) (mg\u002FdL); or,\n\n  * Alanine transaminase (ALT) or Alanine transaminase (AST) ≥ 3x upper limit normal (ULN); or,\n  * Alkaline phosphatase ≥ 2x ULN\n* Severe cardiovascular disease (e.g., current unstable angina, current congestive heart failure, or current severe valvular abnormalities) that is self-reported by patient or in medical record\n* Current valproate, clobazam, or warfarin use per self-report or medical records\n* Current use of strong inducers of cytochrome p450 (CYP) enzymes CYP3A4 and CYP2C19, or CYP2C19 substrates with a narrow therapeutic index\n* Self-reported allergies to sesame oil, strawberries, opioids, or cannabis\u002Fcannabinoids and confirmed by the investigator during screening\n* Any impairment, activity, behavior, or situation that in the judgment of the study team would prevent satisfactory completion of the study protocol\n* Self-reported severe side effects to opioids precluding the use of opioids for post-surgical pain and\u002For clear plan not to use any opioids after surgery and confirmed by the investigator during screening\n* Participation in other clinical trials over the course of this study (note: outside of active period is permissible as determined by the investigator during screening)","ALL","18 Years","80 Years",{"count":21,"type":22},380,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The goal of this study is to better understand how daily treatment with cannabidiol (CBD) affects the need for opioid pain medication, as well as pain, inflammation and other related symptoms, after knee replacement surgery. The information collected in this study is necessary to help understand whether CBD may be a useful medication before and\u002For after surgery.\n\nThe study hypothesis is that CBD exerts opioid-sparing effects through anti-inflammatory, analgesic, and anxiolytic mechanisms.",[28,29],"Knee Replacement Surgery","Osteoarthritis, Knee",[31,32],"Epidiolex","Pain medication","RECRUITING","2026-04-12",{"date":36,"type":37},"2026-04-15","ACTUAL",{"date":39,"type":37},"2024-03-13",{"date":41,"type":22},"2029-01",{"name":43,"class":44},"Chad Brummett","OTHER",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100587849","effect-of-virtual-reality-on-patient-outcomes-and-satisfaction-in-total-knee-replacement-100587849","NCT06933732","Effect of Virtual Reality on Patient Outcomes and Satisfaction in Total Knee Replacement","The Effect of Virtual Reality Applications on Patient Outcomes and Satisfaction Before and After Total Knee Replacement: A Randomised Controlled Study","Inclusion Criteria:\n\n* Patients with an ASA score of 1, 2, or 3\n* Elective unilateral total knee replacement surgery was planned,\n* Patients who are able to read and write in Turkish\n\nExclusion Criteria:\n\n* Using \\>30 mg of oral oxycodone or equivalent daily\n* Long-term opioid use (\\>12 weeks)\n* Substance use disorder\n* Scheduled for emergency surgery\n* Scheduled for revision surgery\n* Requiring postoperative intensive care\n* Patients with visual or hearing impairments\n* Individuals experiencing motion-related nausea or dizziness\n* History of stroke or dementia\n* Pregnant or breastfeeding women\n* Patients with a history of epilepsy or seizures","65 Years",{"count":55,"type":22},64,[57],"NA","This study aims to evaluate the effectiveness of virtual reality (VR) in managing preoperative anxiety and postoperative pain in patients undergoing total knee replacement. Investigators will assess the impact of preoperative VR training on anxiety levels, explore the effectiveness of relaxing and distracting VR videos for pain management after surgery, and determine the optimal timing for VR application by comparing different VR intervention times. Our goal is to identify how VR can improve both the emotional and physical recovery process for patients undergoing knee replacement surgery.",[60,28,61,62,63,64],"Knee Replacement","Postoperative Pain, Acute","Anxiety, Preoperative","Pain Management","Virtual Reality","NOT_YET_RECRUITING","2025-09-23",{"date":68,"type":37},"2025-09-26",{"date":70,"type":22},"2025-12-25",{"date":72,"type":22},"2026-03-31",{"name":74,"class":44},"Aykut Turgut",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":95,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":45},"100512299","phase-4-mini-dose-dexmedetomidine-esketamine-infusion-and-perioperative-sleep-quality-100512299","NCT05950646","Mini-dose Dexmedetomidine-Esketamine Infusion and Perioperative Sleep Quality","Effect of Mini-dose Dexmedetomidine-Esketamine Infusion on Sleep Quality in Older Patients Undergoing Knee or Hip Replacement Surgery: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥65 years and \\\u003C90 years;\n* Scheduled to undergo unilateral knee or hip arthroplasty.\n\nExclusion Criteria:\n\n* Refuse to participate;\n* Hypnotic therapy for sleep disorders within 3 months;\n* Preoperative history of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis;\n* Diagnosed as obstructive sleep apnea, or at high risk of moderate to severe obstructive sleep apnea according to the Stop-Bang questionnaire;\n* Inability to communicate in the preoperative period because of coma, profound dementia, or language barrier;\n* Sick sinus syndrome, severe sinus bradycardia (heart rate \\\u003C50 beats\u002Fmin), or atrioventricular block above grade II without pacemaker implanted;\n* Severe hepatic dysfunction (Child-Pugh class C), renal dysfunction (required preoperative dialysis), or expected survival ≤24 hours;\n* Receiving treatment with dexmedetomidine, clonidine, or esketamine;\n* Allergy to dexmedetomidine or esketamine.","90 Years",{"count":85,"type":22},154,[87],"PHASE4","Sleep disturbances are prevalent in older patients with osteoarthrosis or fracture who are scheduled for knee or hip replacement surgery. The occurrence of sleep disturbances is associated with worse outcomes including increased risk of delirium and cardiac events, and worsened functional recovery. Dexmedetomidine is a highly selective α2-adrenergic agonist with sedative, anxiolytic, and analgesic properties. It exerts sedative effects via activating the endogenous sleep pathways and produces a state like non-rapid eye movement sleep, which is different from opioid- and benzodiazepine-induced sedation. Esketamine is a N-methyl-D-aspartic acid receptor antagonist and has been used as an anesthetic and analgesic. Recent studies showed that low-dose esketamine has anti-depressive and sleep-promoting effects. The investigators suppose that mini-dose dexmedetomidine-esketamine combined infusion at night can improve perioperative sleep quality in patients scheduled for knee or hip replacement surgery.",[90,28,91,92,93,94],"Old Age","Hip Replacement Surgery","Dexmedetomidine","Esketamine","Sleep Quality",[90,28,91,92,93,94],"2025-07-29",{"date":98,"type":37},"2025-07-30",{"date":100,"type":37},"2023-11-01",{"date":102,"type":22},"2025-12",{"name":104,"class":44},"Peking University First Hospital"]